Biohaven (BHVN) Liabilities and Shareholders Equity (2021 - 2026)

Biohaven has disclosed Liabilities and Shareholders Equity across 6 years of filings, most recently posting $466.4 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $466.4 million, up 1.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.9 billion (down 13.37% YoY), and the FY2025 annual result was $451.4 million, down 26.61% from the prior year.
• Liabilities and Shareholders Equity came in at $466.4 million for Q1 2026 at Biohaven, up from $451.4 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $661.8 million in Q4 2022 to a low of $135.6 million in Q3 2022.
• The 5-year median for Liabilities and Shareholders Equity is $506.7 million (2023), against an average of $485.5 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 365.84% in 2022 and tumbled 32.33% in 2024, its largest moves.
• Biohaven's Liabilities and Shareholders Equity stood at $661.8 million in 2022, then dropped by 22.45% to $513.2 million in 2023, then gained by 19.85% to $615.1 million in 2024, then fell by 26.61% to $451.4 million in 2025, then increased by 3.31% to $466.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $466.4 million (Q1 2026), $451.4 million (Q4 2025), and $409.1 million (Q3 2025), per Business Quant data.